


wherein said aryl, heteroaryl and heterocyclyl groups of $\text{NR}^{4b}\text{R}^{5b}$ may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, halo C_{1-6} alkyl, polyhalo C_{1-6} alkyl, halo C_{1-6} alkoxy, polyhalo C_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, aryl C_{1-6} alkyl, heteroaryl C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl C_{1-6} alkyl, aryl C_{1-6} alkanoyl, or a group $-\text{NR}^{15b}\text{R}^{16b}$, $-\text{CONR}^{15b}\text{R}^{16b}$, $-\text{NR}^{15b}\text{COR}^{16b}$, $-\text{NR}^{15b}\text{SO}_2\text{R}^{16b}$ or $-\text{SO}_2\text{NR}^{15b}\text{R}^{16b}$, wherein R^{15b} and R^{16b} independently represent hydrogen or C_{1-6} alkyl;
 X^b represents a bond, CO, NHCO or CONH;


or R^1 represents a group of formula (C):



(C)

wherein R^{4c} represents C_{1-6} alkyl, OH, aryl or heterocyclyl, wherein said aryl and heterocyclyl groups may be optionally substituted by halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, oxo, trifluoromethyl or an aryl group;
 r is 0, 1 or 2;


or R^1 represents a group of formula (D):



(D)

wherein R^{4d} represents aryl or heteroaryl wherein said aryl and heteroaryl groups may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;
 X^d represents a bond or NHCO, such that when X^d represents NHCO, the group $\text{R}^{4d}-\text{X}^d$ is attached at the 3-position of the pyrrolidinyl ring;

or R^1 represents a group of formula $-\text{CO}-\text{E}$, wherein E represents a group of formula E^a , E^b or E^c :



wherein X^e represents O or N-R^{8e};

Y^e represents -C(HR^{9e})- or -C(=O)-;

5 R^{4e}, R^{5e}, R^{8e} and R^{9e} independently represent hydrogen, C₁₋₆ alkyl, aryl, heteroaryl, -C₁₋₆ alkyl-aryl or -C₁₋₆ alkyl-heteroaryl;


R^{6e} and R^{7e} independently represent hydrogen, C₁₋₆ alkyl, aryl, heteroaryl, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-heteroaryl or R^{6e} and R^{7e} together with the carbon atoms to which they are attached may form a benzene ring;

10 ----- is a single or double bond;

wherein said aryl or heteroaryl groups of R^{4e}, R^{5e}, R^{6e}, R^{7e}, R^{8e} and R^{9e} may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of C₁₋₆ alkyl, CF₃, C₁₋₆ alkoxy, halogen, cyano, sulfonamide or C₁₋₆ alkylsulfonyl;

15

or R¹ represents a group of formula (F):



wherein t is 0, 1 or 2;

20 u is 1 or 2;

R^{4f} represents C₁₋₆ alkyl or when t represents 2, said R^{4f} groups may instead form a bridging group consisting of one or two methylene groups;

R^{5f} represents -C₁₋₆ alkyl, -C₁₋₆ alkylC₁₋₆ alkoxy, -C₃₋₈ cycloalkyl, aryl, heterocyclyl, heteroaryl, -C₁₋₆ alkyl-aryl, -C₁₋₆ alkyl-C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-heteroaryl, -C₁₋₆ alkyl-heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl or -heterocyclyl-heterocyclyl;


25 wherein R^{5f} may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC₁₋₆ alkyl, polyhaloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, polyhaloC₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, or a group
30 NR^{15f}R^{16f}, -CONR^{15f}R^{16f}, -NR^{15f}COR^{16f}, -NR^{15f}SO₂R^{16f} or -SO₂NR^{15f}R^{16f}, wherein R^{15f} and R^{16f} independently represent hydrogen or C₁₋₆ alkyl or together form a heterocyclic ring;

Z^1 represents CO or SO₂;

R^2 represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2;

- 5 R^3 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



wherein q is 2, 3 or 4;

- 10 R^{11} and R^{12} independently represent C₁₋₆ alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group selected from pyrrolidine, piperidine and homopiperidine optionally substituted by one or two R^{17} groups;

R^{13} represents C₁₋₆ alkyl, C₃₋₆ cycloalkyl or $-C_{1-4}$ alkyl-C₃₋₆ cycloalkyl;

- 15 R^{14} and R^{17} independently represent halogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, OH, diC₁₋₆ alkylamino or C₁₋₆ alkoxy;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; or solvates thereof.

20

2. A compound according to claim 1 which is a compound of formula E1-E172 or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises the compound of
25 formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4. A compound as defined in claim 1 or claim 2 for use in therapy.

- 30 5. A compound as defined in claim 1 or claim 2 for use in the treatment of neurological diseases.

6. Use of a compound as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment of neurological diseases.

35

7. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

5